Stock Price & Analysis

The S1 support level for BCAX Stock is $12.07 ,The R1 resistant level for BCAX Stock is $14.49.

As of the end of day on 2025-03-06, the price of BCAX Stock was $14.79.

The target price for BCAX Stock according to analyst rating is 39.75, with the highest price target at 47.00 and the lowest at 31.00. Analysts have a Strong Buy rating on BCAX Stock overall.

The market cap of BCAX is $809.7M.

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.

BCAX has a total of 32 employees.